Inactive Instrument

Xintela AB (publ) Stock price Nasdaq Stockholm

Equities

SE0007756903

Biotechnology & Medical Research

Sales 2021 - Sales 2022 - Capitalization 151M 14.14M
Net income 2021 -59M -5.54M Net income 2022 -66M -6.2M EV / Sales 2021 -
Net cash position 2021 11.14M 1.05M Net cash position 2022 8.34M 784K EV / Sales 2022 -
P/E ratio 2021
-3.19 x
P/E ratio 2022
-1.33 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 31.28%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 67 08-12-31
Director of Finance/CFO 63 12-12-31
Corporate Officer/Principal 52 17-02-28
Members of the board TitleAgeSince
Director/Board Member 67 20-12-31
Chairman 67 10-12-31
Director/Board Member 64 -
More insiders
Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Xintela AB
  4. Stock Xintela AB (publ) - Nasdaq Stockholm